Valuation : Matricelf Ltd

Market Cap 90.85M 0 30.18M 25.97M 24.43M 22.32M 41.75M 2.85B 41.87M 289M 112M 1.46B 113M 111M 4.71B P/E 2024
-3.74x
P/E 2025 -3.65x
Enterprise Value 70.71M 0 23.49M 20.21M 19.02M 17.37M 32.5M 2.22B 32.59M 225M 87.2M 1.14B 88.2M 86.28M 3.67B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
77.85%
Yield 2024 *
-
Yield 2025 -
1 day+2.36%
1 week+16.21%
Current month+12.97%
1 month+16.21%
3 months+15.40%
6 months-39.76%
Current year-45.60%
1 week 259.5
Extreme 259.5
316.1
1 month 238
Extreme 238
316.1
Current year 212
Extreme 212
853
1 year 212
Extreme 212
853
3 years 204
Extreme 204
853
5 years 204
Extreme 204
1,555
10 years 204
Extreme 204
1,555
Manager TitleAgeSince
Chief Executive Officer 54 31/05/2019
Chief Tech/Sci/R&D Officer 51 31/05/2019
Chief Operating Officer 59 30/06/2019
Director TitleAgeSince
Director/Board Member 59 30/06/2019
Director/Board Member 51 31/05/2019
Director/Board Member 68 26/07/2022
Change 5-day change 1-year change 3-year change Capi.($)
+2.36%+16.21%-53.06%-30.98% 30.18M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.59%+2.10%+59.93%+94.01% 27.5B
Weighted average by Cap. -1.03%+0.11%+89.40%+127.91%

Financials

2024 2025
Net sales - -
Net income -15.58M -0 -5.18M -4.45M -4.19M -3.83M -7.16M -489M -7.18M -49.52M -19.21M -251M -19.44M -19.01M -808M -27.82M -0 -9.24M -7.95M -7.48M -6.83M -12.79M -873M -12.82M -88.41M -34.31M -448M -34.7M -33.95M -1.44B
Net Debt -10.68M -0 -3.55M -3.05M -2.87M -2.62M -4.91M -335M -4.92M -33.94M -13.17M -172M -13.32M -13.03M -554M -20.14M -0 -6.69M -5.76M -5.42M -4.95M -9.26M -632M -9.28M -64M -24.84M -324M -25.12M -24.57M -1.04B
Logo Matricelf Ltd
Matricelf Ltd is an Israel-based company engaged in the biotechnology sector. The Company operates in the field of tissue engineering and regenerative medicine. The Firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The Company focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University.
Employees
-
Date Price Change Volume
04/09/26 ILA 299.70 +2.36% 193,320
03/09/26 ILA 292.80 +6.55% 206,055
02/09/26 ILA 274.80 +0.04% 290,279
01/09/26 ILA 274.70 +3.54% 195,511
31/08/26 ILA 265.30 +2.87% 97,306
  1. Stock Market
  2. Stocks
  3. MTLF Stock